[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Paolo Manzoni Study Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100553530",false,"NCT06487286","Levels of Visfatin\u002FNAMPT in Human Milk","Levels of Visfatin\u002FNAMPT in Human Milk.VISFAMILK","VISFAMILK","Inclusion Criteria:\n\n* Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities\n* Maternal hospitalization\n* Acquisition of the informed consent form signed by the patient\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study\n* Presence of hypogalactia or agalactia in the patient","ALL",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic\u002Fpredictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.",[23,24],"Visfatin Levels in Maternal Milk Samples","Birth Weight",[26,27,28],"Newborns","Visfatin","Breastfeeding","RECRUITING","2024-11-12",{"date":32,"type":33},"2024-11-14","ACTUAL",{"date":35,"type":33},"2024-10-24",{"date":37,"type":19},"2025-04-23",{"name":39,"class":40},"Paolo Manzoni Study Group","OTHER",""]